GENOMMA LAB ANNOUNCES REFINANCING OF LONG-TERM LIABILITIES AND RELEASE OF REAL ESTATE COLLATERAL MEXICO CITY , July 22, 2024 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V . (BMV: LABB) ("Genomma Lab" or "the Company"), a leading company in the pharmaceutical and personal care industry in Mexico with a growing international presence, announces that it has secured a long-term credit line, refinanced financial liabilities, and obtained the release of real estate collateral tied to existing loans.
Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024 SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the market.
Standard BioTools Shareholders Back Growth and Governance Plans Standard BioTools (LAB) has issued an announcement. Standard BioTools Inc. successfully conducted its 2024 Annual Meeting, where stockholders showe…
GENOMMA LAB INTERNACIONAL ANNOUNCES EIGHTH DIVIDEND PAYMENT MEXICO CITY , June 13, 2024 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N.
Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers | LAB Stock News Standard BioTools acquires Carterra LSAXT system to advance SomaScan Platform, enhancing protein binding validation and accelerating biomarker discovery. Learn more.
Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSAXT system from Carterra®, a leading provider of high-throughput large and small molecule screening and characterization solutions. This instrument will enable Standard BioTools™ to further validate its SomaScan® Platform by measuring the kinetic properties of SOMAmer® Reagents and deliver precise information about protein binding and biomarker characterization to customers.
Standard BioTools to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that its management team will participate in the following investor conferences in the month of June: Jefferies Global Healthcare Conference on June 5th & 6th 2024.
Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that the Human Capital Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of May 20, 2024, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan (Plan).
Earnings call: Standard BioTools achieves growth and synergy targets in Q1 https://www.investing.com/news/stock-market-news/earnings-call-standard-biotools-achieves-growth-and-synergy-targets-in-q1-93CH-3436438